@article { author = {Ayatollahi, Hossein and Bazi, Ali and Sadeghian, Mohammad Hadi and Fani, Ali and Siyadat, Payam and Sheikhi, Maryam and Sargazi-aval, Omolbanin}, title = {The Survival of Patients with t(15;17)(q22;q12) Positive Acute Promyelocytic Leukemia: A Study in North-East of Iran}, journal = {Iranian Journal of Pathology}, volume = {15}, number = {3}, pages = {175-181}, year = {2020}, publisher = {Farname Inc in collaboration with Iranian Society of Pathology}, issn = {1735-5303}, eissn = {2345-3656}, doi = {10.30699/ijp.2020.101417.2007}, abstract = {Background & Objective: Acute promyelocytic leukemia (APL) with t(15;17)(q22;q12) is a relatively common subtype of acute myeloid leukemia (AML).  Here, our objective was to ascertain the survival of patients with this leukemia in north-east of Iran. Methods:  Survival rates of 42 APL patients with t(15;17)(q22;q12) were assessed. Clinical information was obtained from archived medical records. Statistical analysis was performed by SPSS 18 software using log-ranked test and Kaplan Maier survival analysis. Results: Females and males comprised 49% and 51%, respectively. The mean age at diagnosis was 34.3 ± 14.1 years old. During the study period, 17 demises occurred in males, while this number was 7 in females. The mean survival of patients (month) was 23.22 ± 3.57 (95% CI: 16.21 ± 30.2). The five-year survival rate obtained 30%. Regarding demographic and clinical features, the highest rates of 5-year survival were recorded in patients with 20-35 years old (47.6%), males (51%), white blood cell count <10±/l (48%), and platelet count >140 ± /l (100%). Conclusion: Younger age, lower WBC count and higher platelet count were significantly associated with longer survival in AML patients with t(15;17)(q22; q12).}, keywords = {Acute myeloid leukemia, Acute promyelocytic leukemia, Blood cancer, Survival, t(15,17)(q22,q12)}, url = {https://ijp.iranpath.org/article_39854.html}, eprint = {https://ijp.iranpath.org/article_39854_46fc0465453397d920595d40e90c7b80.pdf} }